Dec. 14, 2023 – The biotech company MAPS Public Benefit Corporation (MAPS PBC) is a step closer to official approval for its MDMA-based therapy that supposedly treats post-traumatic stress disorder (PTSD). If approved, MDMA would then have to be rescheduled so it can be available as a prescription medication.
The proposed therapy uses “a combination of MDMA, psychotherapy (also known as talk therapy) and other supportive services to treat PTSD,” the release stated. A 2021 meta-analysis in the Journal of Clinical Pharmacology found that although “MDMA-assisted psychotherapy has been shown to be an effective therapy for patients with PTSD with a reasonable safety profile, use of unregulated MDMA or use in the absence of a strongly controlled psychotherapeutic environment has considerable risks.”
MEASLY AMOUNT – May 3, 2024 - Amneal Pharmaceuticals reached an agreement to pay…
VIDEO – THE ANGEL WEARS NADA – Mar. 26, 2024 - “I knew deep…
HIGHER POWER BARK – April 29, 2024 - An Arizona-based nonprofit has reached the…
VIDEO ONLY – ONE WILL GET YOU TEN – May, 2024 - Actor, Tom…
VIDEO – GOOD MORNING - NOT – May 2, 2024 - A Kentucky boy…
VIDEO – ONE LAST SHOT – May 1, 2024 - His family says he…